Overview
Naftopidil is a selective alpha-1 adrenergic receptor antagonist with particular affinity for the alpha-1D receptor subtype. Developed as a therapeutic agent, it has found significant application in urology for treating benign prostatic hyperplasia (BPH) and in cardiology for managing hypertension. The compound was first synthesized in Japan and has been clinically used since the 1990s. Pharmacologically, naftopidil differs from other alpha-blockers by its unique receptor subtype selectivity profile. This characteristic contributes to its therapeutic efficacy while potentially reducing side effects commonly associated with non-selective alpha-blockers. The drug is typically administered as naftopidil hydrochloride in oral tablet formulations.
Physical and Chemical Properties
Naftopidil appears as a white to off-white crystalline powder with a melting point range of 137-140°C. Its molecular weight of 392.49 g/mol reflects its moderately sized organic structure containing both aromatic and aliphatic components. The compound demonstrates good solubility in methanol and ethanol but limited solubility in water, which influences its formulation development. The chemical stability of naftopidil is maintained when stored under recommended conditions (2-8°C in airtight containers protected from light). Its hydrochloride salt form enhances stability and bioavailability. The molecular structure features a naphthalene ring system connected to a piperazine derivative, which is crucial for its receptor binding activity.
Main Applications
The primary medical application of naftopidil is in the treatment of benign prostatic hyperplasia (BPH), where it relieves urinary obstruction symptoms by relaxing smooth muscle in the prostate and bladder neck. Clinical studies have shown its efficacy in improving International Prostate Symptom Scores (IPSS) and increasing urinary flow rates. In cardiovascular medicine, naftopidil is used as an antihypertensive agent due to its vasodilatory effects. Some research suggests potential applications in treating chronic pelvic pain syndrome and certain types of urinary incontinence. The typical dosage ranges from 25-75 mg daily, adjusted based on patient response and tolerability.
Safety and Storage
Naftopidil should be handled as a pharmaceutical active ingredient with appropriate precautions. While not classified as highly toxic, exposure to fine powder should be minimized through proper engineering controls and personal protective equipment. The compound is stable under recommended storage conditions but may degrade when exposed to moisture, heat, or prolonged light. From a clinical safety perspective, the most common adverse effects include dizziness, headache, and orthostatic hypotension. These are typically mild to moderate in severity. Contraindications include severe hepatic impairment and known hypersensitivity to the drug. Patients should be cautioned about potential dizziness, especially when initiating therapy.
B2B Procurement Guide
Pharmaceutical manufacturers seeking naftopidil should prioritize suppliers with demonstrated GMP compliance and proper documentation of synthesis pathways. The reference price range of $50-$150/kg varies based on quantity, purity specifications (typically ≥98%), and supplier reputation. Key procurement considerations include verifying analytical certificates (COA), residual solvent profiles, and impurity specifications. Bulk purchases may offer cost advantages but require validation of long-term stability under proposed storage conditions. Quality audits of API manufacturers are recommended, particularly for new suppliers. Transportation should maintain temperature control to preserve compound integrity.